• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Tuesday, November 17, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Updated Guidelines Recommend Regular Prostate Cancer Screening Starting at Age 50

by
November 17, 2026
in Health
Reading Time: 3 mins read
0
Updated Guidelines Recommend Regular Prostate Cancer Screening Starting at Age 50

Updated Guidelines Recommend Regular Prostate Cancer Screening Starting at Age 50

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

The American Cancer Society has released updated clinical guidelines for prostate cancer screening, establishing a proactive recommendation that average-risk men between the ages of 50 and 69 undergo prostate-specific antigen testing every two years. The new guidance also establishes that Black men and individuals with a significant family history of prostate cancer should begin annual screening earlier, starting at age 45, to address heightened disease risks in these groups.

Representing the organization’s first formal revision to its prostate screening framework since 2010, the recommendations were developed by a panel of cancer specialists led by Andrew Wolf, MD, professor emeritus of medicine at the University of Virginia School of Medicine and chair of the American Cancer Society’s Guideline Development Group. Wolf emphasized that the panel moved to a proactive stance because cumulative clinical evidence demonstrates that the benefits of screening—specifically in preventing advanced metastatic disease and decreasing prostate cancer deaths—outweigh the potential harms.

Prostate cancer remains the most frequently diagnosed malignancy among men in the United States and ranks as the second-leading cause of male cancer mortality, responsible for more than 36,000 deaths annually. The disease exhibits pronounced demographic disparities across the nation, with mortality rates among Black men running roughly twice as high as those observed among white men, underscoring the panel’s focus on earlier and more frequent surveillance for populations at elevated risk.

Under the previous 2010 recommendations, the American Cancer Society advised that men consult individually with their physicians to deliberate whether to pursue prostate-specific antigen screening. In the subsequent years, however, an expanding body of research documented that routine blood-based testing significantly improves outcomes by identifying aggressive malignancies early enough to intervene effectively and preserve patient lives.

Robert Smith, PhD, senior author of the guidelines and senior vice president of early cancer detection science at the American Cancer Society, noted that testing remains central to early detection while modern diagnostic pathways have evolved. Smith explained that clinicians now possess improved tools to distinguish potentially lethal tumors from indolent, slow-growing cancers that do not necessitate immediate aggressive therapies, positioning the initial blood test as merely the first phase of a broader diagnostic evaluation.

For older demographics, the updated guidance outlines tailored age-stratified criteria reflecting the typically indolent progression of prostate tumors. For men aged 70 to 74, doctors are instructed to employ an individualized decision-making approach that balances potential diagnostic rewards against the risks of false-positive results and invasive biopsies, while screening is generally discouraged for men aged 75 and older, though healthy individuals aged 75 to 79 with rising marker levels may evaluate continuation with their physician; screening is explicitly not recommended for men aged 80 and older or those with a life expectancy under ten years.

To refine the diagnostic sequence for men aged 45 to 74 who exhibit elevated prostate-specific antigen levels, the protocol requires a confirmatory repeat blood test within an interval of two weeks to three months.

If a secondary blood test confirms persistently high antigen concentrations, the guidelines mandate secondary noninvasive diagnostics before directing a patient to an invasive tissue biopsy. Clinicians are directed to confirm the elevated reading using magnetic resonance imaging, advanced urine assays, or blood biomarker assessments to establish whether a biopsy is genuinely necessary, thereby mitigating unnecessary procedures.

Wolf expressed confidence that wide adherence to these updated pathways by patients and clinicians will yield measurable declines in advanced metastatic cases and overall prostate cancer deaths over the coming years.

The complete clinical recommendations are published open access in CA: A Cancer Journal for Clinicians by an interdisciplinary author group including Richard M. Hoffman, Andrew Wolf, Robert Smith, and colleagues across leading cancer research centers. The developmental efforts also reflect ongoing translational initiatives at the National Cancer Institute-designated UVA Comprehensive Cancer Center and the Paul and Diane Manning Institute of Biotechnology aimed at improving early cancer detection and therapeutic development.

Subject of Research: Updated prostate cancer screening guidelines from the American Cancer Society

Article Title: Prostate cancer screening guidelines updated — see what's changed

Article References: Prostate cancer screening guidelines updated — see what's changed. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: prostate cancer, prostate-specific antigen, PSA screening, American Cancer Society, cancer screening guidelines, early cancer detection, active surveillance, prostate biopsy, magnetic resonance imaging, biomarkers, cancer mortality, Black men health disparities, Andrew Wolf, Robert Smith, CA: A Cancer Journal for Clinicians, UVA Comprehensive Cancer Center

News Source: Nathaniel Bowman. (November 17, 2026). Updated Guidelines Recommend Regular Prostate Cancer Screening Starting at Age 50. Scienmag.

Tags: active surveillanceAmerican Cancer SocietyAndrew WolfbiomarkersBlack men health disparitiesCA: A Cancer Journal for Clinicianscancer mortalitycancer screening guidelinesEarly cancer detectionmagnetic resonance imagingprostate biopsyProstate Cancerprostate-specific antigenPSA screeningRobert SmithUVA Comprehensive Cancer Center
Share12Tweet7Share2ShareShareShare1

Related Posts

QL1706 With Chemotherapy Shows Disease Control in Rare Ureteral Cancer Case

QL1706 With Chemotherapy Shows Disease Control in Rare Ureteral Cancer Case

November 17, 2026
Linked Death Records Shift Cardiac Cause Estimates in Zhejiang Cardiac Arrests

Linked Death Records Shift Cardiac Cause Estimates in Zhejiang Cardiac Arrests

November 17, 2026

Review finds disease prevention guidance prioritizes genetic risk over modifiable factors

November 17, 2026

Study Finds Only Sixteen Percent of Ethiopian Mothers Complete Continuum of Care

November 17, 2026

POPULAR NEWS

  • Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    Plane-Based Gonial Angle Segmentation Better Represents Mandibular Growth in Longitudinal Study

    29 shares
    Share 12 Tweet 7
  • Quality Improvement Project Raises Pre-Antibiotic Microbiological Analysis Rate to 79.2 Percent

    29 shares
    Share 12 Tweet 7
  • LLM-Driven Social Simulations Face Significant Epistemic Validity Challenges

    29 shares
    Share 12 Tweet 7
  • Veterinary Brucellosis Testing Requires Validated Decision Rules Across Animal Populations

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

QL1706 With Chemotherapy Shows Disease Control in Rare Ureteral Cancer Case

Linked Death Records Shift Cardiac Cause Estimates in Zhejiang Cardiac Arrests

Review finds disease prevention guidance prioritizes genetic risk over modifiable factors

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 88 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.